Literature DB >> 8457389

Apolipoprotein (a) concentrations and susceptibility to coronary artery disease in patients with peripheral vascular disease.

P Groves1, A Rees, A Bishop, R Morgan, M Ruttley, N Lewis, I Lane, R Hall.   

Abstract

OBJECTIVE: To investigate the relation between apolipoprotein(a) concentrations and angiographically defined coronary artery disease in patients with atheromatous peripheral vascular disease.
DESIGN: 40 consecutive patients were recruited at the time of admission for peripheral vascular surgery. All underwent clinical assessment and coronary arteriography. Apolipoprotein(a) concentrations were measured by an immunoradiometric assay.
SETTING: Tertiary referral centre.
SUBJECTS: Patients requiring surgical intervention for large vessel peripheral vascular disease. MAIN OUTCOME MEASURES: Presence or absence and severity and distribution of angiographically defined coronary artery disease. Measurement of circulating contractions of apolipoprotein(a) and other lipid indices.
RESULTS: Coronary artery disease was absent in 11 patients (group 1), mild to moderate in 12 (group 2), and severe in 17 (group 3). The distribution of peripheral vascular disease and of standard lipid indices was similar in these three groups of patients. There was a significant difference in apolipoprotein(a) concentrations between the three groups, with concentrations progressively increasing with the severity of coronary artery disease (mean (95% confidence interval): group 1, 112 U/1 (52 to 242); group 2, 214 U/1 (129 to 355); group 3, 537 U/1 (271 to 1064) (analysis of variance p < 0.005). The prevalence of coronary artery disease was increased 7.4 fold in patients with apolipoprotein(a) concentrations that were greater than the cohort median (206 U/1) (p < 0.01).
CONCLUSIONS: The results show an association between apolipoprotein(a) concentrations and angiographically defined coronary artery disease in patients with large vessel peripheral vascular disease. The findings imply differences in the pathogenesis of coronary and peripheral atheroma and suggest that the measurement of apolipoprotein(a) may prove a useful additional tool in the risk factor assessment of patients undergoing peripheral vascular surgery.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8457389      PMCID: PMC1024911          DOI: 10.1136/hrt.69.1.26

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  43 in total

1.  Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol.

Authors:  G R Warnick; T Nguyen; A A Albers
Journal:  Clin Chem       Date:  1985-02       Impact factor: 8.327

2.  Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction.

Authors:  A Murai; T Miyahara; N Fujimoto; M Matsuda; M Kameyama
Journal:  Atherosclerosis       Date:  1986-02       Impact factor: 5.162

3.  Lipoprotein Lp(a) and the risk for myocardial infarction.

Authors:  G M Kostner; P Avogaro; G Cazzolato; E Marth; G Bittolo-Bon; G B Qunici
Journal:  Atherosclerosis       Date:  1981 Jan-Feb       Impact factor: 5.162

4.  Serum concentrations of Lp(a) and other lipoprotein parameters in heavy alcohol consumers.

Authors:  E Marth; G Cazzolato; G Bittolo Bon; P Avogaro; G M Kostner
Journal:  Ann Nutr Metab       Date:  1982       Impact factor: 3.374

5.  Haemostatic factors in human aortic intima.

Authors:  E B Smith; E M Staples
Journal:  Lancet       Date:  1981-05-30       Impact factor: 79.321

6.  Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management.

Authors:  N R Hertzer; E G Beven; J R Young; P J O'Hara; W F Ruschhaupt; R A Graor; V G Dewolfe; L C Maljovec
Journal:  Ann Surg       Date:  1984-02       Impact factor: 12.969

7.  Determination of cardiac risk by dipyridamole-thallium imaging before peripheral vascular surgery.

Authors:  C A Boucher; D C Brewster; R C Darling; R D Okada; H W Strauss; G M Pohost
Journal:  N Engl J Med       Date:  1985-02-14       Impact factor: 91.245

8.  Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment.

Authors:  A Gurakar; J M Hoeg; G Kostner; N M Papadopoulos; H B Brewer
Journal:  Atherosclerosis       Date:  1985-11       Impact factor: 5.162

9.  Lipoprotein(a) as a strong indicator for cerebrovascular disease.

Authors:  G Zenker; P Költringer; G Boné; K Niederkorn; K Pfeiffer; G Jürgens
Journal:  Stroke       Date:  1986 Sep-Oct       Impact factor: 7.914

10.  The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels.

Authors:  V W Armstrong; P Cremer; E Eberle; A Manke; F Schulze; H Wieland; H Kreuzer; D Seidel
Journal:  Atherosclerosis       Date:  1986-12       Impact factor: 5.162

View more
  2 in total

Review 1.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

2.  A physiological function for apolipoprotein(a): a natural regulator of the inflammatory response.

Authors:  Jane Hoover-Plow; Erika Hart; Yanqing Gong; Aleksey Shchurin; Tracey Schneeman
Journal:  Exp Biol Med (Maywood)       Date:  2008-11-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.